Key result
Long-term lymphoma survivors treated with mediastinal radiotherapy had significantly lower left ventricular ejection fraction (53% vs 60%; P<0.001) and higher native myocardial T1 than healthy controls.
Why the study?
Long-term lymphoma survivors experience late radiotherapy and anthracycline toxicities causing premature cardiovascular morbidity and mortality, prompting the identification of subclinical cardiovascular disease markers using CMR.
Does cardiovascular magnetic resonance detect subclinical cardiovascular disease in long-term survivors of lymphoma treated with radiotherapy and/or anthracyclines compared to healthy controls?
Population
80 lymphoma survivors treated with mediastinal radiotherapy and 40 matched healthy control subjects
Comparison
Lymphoma survivors vs age- and sex-matched healthy controls
Design
Case-control study
Authors
Loading...
Highlights potential long-term cardiotoxicity after mediastinal radiotherapy; leaves open whether T1 mapping aids risk stratification in survivors.
Case-Control (n=120)
Does cardiovascular magnetic resonance detect subclinical cardiovascular disease in long-term survivors of lymphoma treated with radiotherapy and/or anthracyclines compared to healthy controls?
Absolute Event Rate: 53% vs 60%
p-value: p=<0.001
Long-term lymphoma survivors treated with radiotherapy and anthracyclines exhibit detectable subclinical myocardial dysfunction and tissue changes on CMR compared to healthy controls.
Velde et al. (2021) conducted a case-control in Lymphoma survivors (n=120). Mediastinal radiotherapy with or without anthracyclines vs. Healthy control subjects was evaluated on Left ventricular ejection fraction (p=<0.001). Long-term lymphoma survivors treated with mediastinal radiotherapy had significantly lower left ventricular ejection fraction (53% vs 60%; P<0.001) and higher native myocardial T1 than healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: